{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T03:34:33Z","timestamp":1790393673781,"version":"4.1.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,29]],"date-time":"2024-11-29T00:00:00Z","timestamp":1732838400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,11,29]],"date-time":"2024-11-29T00:00:00Z","timestamp":1732838400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Histologic transformation (HT) of indolent non-Hodgkin lymphoma (iNHL) to diffuse large B-cell lymphoma (DLBCL) carries a poor prognosis. Using the Surveillance, Epidemiology, and End Results-17 database, we conducted a population-based study of adult patients with transformed follicular lymphoma (t-FL), marginal zone lymphoma (t-MZL), lymphoplasmacytic lymphoma\/Waldenstr\u00f6m macroglobulinemia (t-LPL\/WM), and de novo DLBCL. Primary outcome was relative survival (RS), and secondary outcomes included overall survival (OS) and lymphoma-specific survival (LSS). Outcomes were modeled using flexible parametric survival models, while multivariable modeling was used to compare RS, OS, and LSS. The incidence of HT was highest in splenic MZL (SMZL, 6.78%) and lowest in extranodal MZL (EMZL, 1.62%). Median follow-up times were similar for patients with de novo DLBCL and transformed indolent lymphomas. The 5-year RS and OS were longer in de novo DLBCL compared to all other transformed iNHL subtypes (68 versus 59%, respectively). For t-FL, early transformation (within 2 years of diagnosis, Hazard ratio [HR]\u2009=\u20091.34) and prior treatment (HR\u2009=\u20091.89) were associated with inferior survival. This association was not observed in other transformed lymphoma subtypes. This is the first comparative study to show that the outcomes of t-LPL\/WM were inferior compared to de novo DLBCL and highlights the need to incorporate early experimental therapies in patients with t-FL with early transformation and receipt of prior chemotherapy.<\/jats:p>","DOI":"10.1038\/s41408-024-01194-5","type":"journal-article","created":{"date-parts":[[2024,11,29]],"date-time":"2024-11-29T01:51:33Z","timestamp":1732845093000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["A comparative analysis of transformed indolent lymphomas and de novo diffuse large B-cell lymphoma: a population-based cohort study"],"prefix":"10.1038","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8122-3852","authenticated-orcid":false,"given":"John L.","family":"Vaughn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Ramdhanny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7306-8677","authenticated-orcid":false,"given":"Malak","family":"Munir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sravani","family":"Rimmalapudi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8216-3457","authenticated-orcid":false,"given":"Narendranath","family":"Epperla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,29]]},"reference":[{"key":"1194_CR1","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1053\/j.seminhematol.2023.11.002","volume":"60","author":"EM Parry","year":"2023","unstructured":"Parry EM, Roulland S, Okosun J. DLBCL arising from indolent lymphomas: how are they different? Semin Hematol. 2023;60:277\u201384.","journal-title":"Semin Hematol"},{"key":"1194_CR2","doi-asserted-by":"publisher","first-page":"2575","DOI":"10.1200\/JCO.2015.65.7163","volume":"34","author":"C Sarkozy","year":"2016","unstructured":"Sarkozy C, Trneny M, Xerri L, Wickham N, Feugier P, Leppa S, et al. Risk factors and outcomes for patients with follicular lymphoma who had histologic transformation after response to first-line immunochemotherapy in the PRIMA trial. J Clin Oncol. 2016;34:2575\u201382.","journal-title":"J Clin Oncol"},{"key":"1194_CR3","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1111\/bjh.14831","volume":"178","author":"S Alonso-\u00c1lvarez","year":"2017","unstructured":"Alonso-\u00c1lvarez S, Magnano L, Alcoceba M, Andrade-Campos M, Espinosa-Lara N, Rodr\u00edguez G, et al. Risk of, and survival following, histological transformation in follicular lymphoma in the rituximab era. A retrospective multicentre study by the Spanish GELTAMO group. Br J Haematol. 2017;178:699\u2013708.","journal-title":"Br J Haematol"},{"key":"1194_CR4","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1182\/blood-2015-01-621375","volume":"126","author":"ND Wagner-Johnston","year":"2015","unstructured":"Wagner-Johnston ND, Link BK, Byrtek M, Dawson KL, Hainsworth J, Flowers CR, et al. Outcomes of transformed follicular lymphoma in the modern era: a report from the National LymphoCare Study (NLCS). Blood. 2015;126:851\u20137.","journal-title":"Blood"},{"key":"1194_CR5","doi-asserted-by":"publisher","first-page":"3272","DOI":"10.1200\/JCO.2012.48.3990","volume":"31","author":"BK Link","year":"2013","unstructured":"Link BK, Maurer MJ, Nowakowski GS, Ansell SM, Macon WR, Syrbu SI, et al. Rates and outcomes of follicular lymphoma transformation in the immunochemotherapy era: a report from the University of Iowa\/Mayo Clinic Specialized Program of Research Excellence Molecular Epidemiology Resource. J Clin Oncol. 2013;31:3272\u20138.","journal-title":"J Clin Oncol"},{"key":"1194_CR6","doi-asserted-by":"crossref","unstructured":"Florindez J, Chihara D, Reis I, Lossos IS, Alderuccio JP. Risk of transformation by frontline management in follicular and marginal zone lymphomas: a US population-based analysis. Blood Adv. 2024;8:4423-32.","DOI":"10.1182\/bloodadvances.2024013499"},{"key":"1194_CR7","doi-asserted-by":"publisher","first-page":"e359","DOI":"10.1016\/S2352-3026(18)30090-5","volume":"5","author":"M Federico","year":"2018","unstructured":"Federico M, Barrig\u00f3n MDC, Marcheselli L, Tarantino V, Manni M, Sarkozy C, et al. Rituximab and the risk of transformation of follicular lymphoma: a retrospective pooled analysis. Lancet Haematol. 2018;5:e359\u201367.","journal-title":"Lancet Haematol"},{"key":"1194_CR8","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1007\/s00277-015-2303-5","volume":"94","author":"K Lerch","year":"2015","unstructured":"Lerch K, Meyer AH, Stroux A, Hirt C, Keller U, Viardot A, et al. Impact of prior treatment on outcome of transformed follicular lymphoma and relapsed de novo diffuse large B cell lymphoma: a retrospective multicentre analysis. Ann Hematol. 2015;94:981\u20138.","journal-title":"Ann Hematol"},{"key":"1194_CR9","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1111\/bjh.15816","volume":"185","author":"C Rusconi","year":"2019","unstructured":"Rusconi C, Anastasia A, Chiarenza A, Marcheselli L, Cavallo F, Rattotti S, et al. Outcome of transformed follicular lymphoma worsens according to the timing of transformation and to the number of previous therapies. A retrospective multicenter study on behalf of Fondazione Italiana Linfomi (FIL). Br J Haematol. 2019;185:713\u20137.","journal-title":"Br J Haematol"},{"key":"1194_CR10","doi-asserted-by":"publisher","first-page":"5268","DOI":"10.1182\/blood-2019-123466","volume":"134","author":"C Casulo","year":"2019","unstructured":"Casulo C, Herold M, Hiddemann W, Iyengar S, Marcus RE, Seymour JF, et al. Risk factors and outcomes of patients with follicular lymphoma who had histologic transformation at first progression after first-line immunochemotherapy in the Gallium study. Blood. 2019;134:5268.","journal-title":"Blood"},{"key":"1194_CR11","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1093\/annonc\/mdu537","volume":"26","author":"C Madsen","year":"2015","unstructured":"Madsen C, Pedersen MB, Vase M\u00d8, Bendix K, M\u00f8ller MB, Johansen P, et al. Outcome determinants for transformed indolent lymphomas treated with or without autologous stem-cell transplantation. Ann Oncol. 2015;26:393\u20139.","journal-title":"Ann Oncol"},{"key":"1194_CR12","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-023-00525-1","volume":"11","author":"JL Vaughn","year":"2023","unstructured":"Vaughn JL, Epperla N. Survival of patients with transformed follicular lymphoma in the United States: a multiple cohort study. Biomark Res. 2023;11:84.","journal-title":"Biomark Res"},{"key":"1194_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41408-023-00831-9","volume":"13","author":"I Kalashnikov","year":"2023","unstructured":"Kalashnikov I, Tanskanen T, Viisanen L, Malila N, Jyrkki\u00f6 S, Lepp\u00e4 S. Transformation and survival in marginal zone lymphoma: a Finnish nationwide population-based study. Blood Cancer J. 2023;13:1\u20138.","journal-title":"Blood Cancer J"},{"key":"1194_CR14","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1182\/blood-2023-186626","volume":"142","author":"C Bommier","year":"2023","unstructured":"Bommier C, Link BK, Gysbers B, Maurer MJ, Larson MC, Khurana A, et al. Cumulative incidence, predictors, and outcomes of transformation to diffuse large B-cell lymphoma in a prospective cohort of patients with marginal zone lymphoma. Blood. 2023;142:1672.","journal-title":"Blood"},{"key":"1194_CR15","doi-asserted-by":"publisher","first-page":"e1660","DOI":"10.1002\/onco.13846","volume":"26","author":"S Desai","year":"2021","unstructured":"Desai S, Chaturvedi M, Hameed R, Baez-sosa V, Shenoy AG. Single-center analysis of characteristics and outcomes of de novo, concurrent, and transformed diffuse large B-cell lymphoma. Oncologist. 2021;26:e1660\u20133.","journal-title":"Oncologist"},{"key":"1194_CR16","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1002\/ajh.24477","volume":"91","author":"JJ Castillo","year":"2016","unstructured":"Castillo JJ, Gustine J, Meid K, Dubeau T, Hunter ZR, Treon SP. Histological transformation to diffuse large B-cell lymphoma in patients with Waldenstr\u00f6m macroglobulinemia. Am J Hematol. 2016;91:1032\u20135.","journal-title":"Am J Hematol"},{"key":"1194_CR17","doi-asserted-by":"publisher","first-page":"3370","DOI":"10.1200\/JCO.18.00138","volume":"36","author":"JP Alderuccio","year":"2018","unstructured":"Alderuccio JP, Zhao W, Desai A, Gallastegui N, Ramdial J, Kimble E, et al. Risk factors for transformation to higher-grade lymphoma and its impact on survival in a large cohort of patients with marginal zone lymphoma from a single institution. J Clin Oncol. 2018;36:3370\u201380.","journal-title":"J Clin Oncol"},{"key":"1194_CR18","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1002\/ajh.25697","volume":"95","author":"S Zanwar","year":"2020","unstructured":"Zanwar S, Abeykoon JP, Durot E, King R, Perez Burbano GE, Kumar S, et al. Impact of MYD88L265P mutation status on histological transformation of Waldenstr\u00f6m macroglobulinemia. Am J Hematol. 2020;95:274\u201381.","journal-title":"Am J Hematol"},{"key":"1194_CR19","doi-asserted-by":"publisher","first-page":"2329","DOI":"10.1093\/annonc\/mdv368","volume":"26","author":"A Conconi","year":"2015","unstructured":"Conconi A, Franceschetti S, Aprile von Hohenstaufen K, Margiotta-Casaluci G, Stathis A, Moccia AA, et al. Histologic transformation in marginal zone lymphomas. Ann Oncol. 2015;26:2329\u201335.","journal-title":"Ann Oncol"},{"key":"1194_CR20","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/leu.2016.175","volume":"31","author":"A Bouska","year":"2017","unstructured":"Bouska A, Zhang W, Gong Q, Iqbal J, Scuto A, Vose J, et al. Combined copy number and mutation analysis identifies oncogenic pathways associated with transformation of follicular lymphoma. Leukemia. 2017;31:83\u201391.","journal-title":"Leukemia"},{"key":"1194_CR21","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.celrep.2013.12.027","volume":"6","author":"L Pasqualucci","year":"2014","unstructured":"Pasqualucci L, Khiabanian H, Fangazio M, Vasishtha M, Messina M, Holmes AB, et al. Genetics of follicular lymphoma transformation. Cell Rep. 2014;6:130\u201340.","journal-title":"Cell Rep"},{"key":"1194_CR22","doi-asserted-by":"publisher","first-page":"5038","DOI":"10.1182\/bloodadvances.2023010133","volume":"7","author":"N Epperla","year":"2023","unstructured":"Epperla N, Zhao Q, Karmali R, Torka P, Shea L, Oh TS, et al. Impact of detectable monoclonal protein at diagnosis on outcomes in marginal zone lymphoma: a multicenter cohort study. Blood Adv. 2023;7:5038\u201346.","journal-title":"Blood Adv"},{"key":"1194_CR23","doi-asserted-by":"crossref","unstructured":"Grover NS, Annunzio K, Watkins M, Torka P, Karmali R, Anampa-Guzman A, et al. Evaluation of Ki-67 expression and large cell content as prognostic markers in MZL: a multicenter cohort study. Blood Cancer J. 2024;14:182.","DOI":"10.1038\/s41408-024-01162-z"},{"key":"1194_CR24","doi-asserted-by":"publisher","first-page":"3695","DOI":"10.1182\/bloodadvances.2022009415","volume":"7","author":"M Grau","year":"2023","unstructured":"Grau M, L\u00f3pez C, Navarro A, Frigola G, Nadeu F, Clot G, et al. Unraveling the genetics of transformed splenic marginal zone lymphoma. Blood Adv. 2023;7:3695\u2013709.","journal-title":"Blood Adv"},{"key":"1194_CR25","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1056\/NEJMra2102568","volume":"386","author":"D Rossi","year":"2022","unstructured":"Rossi D, Bertoni F, Zucca E. Marginal-zone lymphomas. N Engl J Med. 2022;386:568\u201381.","journal-title":"N Engl J Med"},{"key":"1194_CR26","doi-asserted-by":"publisher","first-page":"2072","DOI":"10.1182\/blood-2015-11-624312","volume":"127","author":"L Arcaini","year":"2016","unstructured":"Arcaini L, Rossi D, Paulli M. Splenic marginal zone lymphoma: from genetics to management. Blood. 2016;127:2072\u201381.","journal-title":"Blood"},{"key":"1194_CR27","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1111\/bjh.15049","volume":"180","author":"SP Treon","year":"2018","unstructured":"Treon SP, Gustine J, Xu L, Manning RJ, Tsakmaklis N, Demos M, et al. MYD88 wild-type Waldenstrom macroglobulinaemia: differential diagnosis, risk of histological transformation, and overall survival. Br J Haematol. 2018;180:374\u201380.","journal-title":"Br J Haematol"},{"key":"1194_CR28","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1002\/ajh.24477","volume":"91","author":"JJ Castillo","year":"2016","unstructured":"Castillo JJ, Gustine J, Meid K, Dubeau T, Hunter ZR, Treon SP. Histological transformation to diffuse large B\u2010cell lymphoma in patients with Waldenstr\u00f6m macroglobulinemia. Am J Hematol. 2016;91:1032\u20135.","journal-title":"Am J Hematol"},{"key":"1194_CR29","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1056\/NEJMoa1801445","volume":"378","author":"R Schmitz","year":"2018","unstructured":"Schmitz R, Wright GW, Huang DW, Johnson CA, Phelan JD, Wang JQ, et al. Genetics and pathogenesis of diffuse large B-cell lymphoma. N Engl J Med. 2018;378:1396\u2013407.","journal-title":"N Engl J Med"},{"key":"1194_CR30","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1038\/s41591-018-0016-8","volume":"24","author":"B Chapuy","year":"2018","unstructured":"Chapuy B, Stewart C, Dunford AJ, Kim J, Kamburov A, Redd RA, et al. Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med. 2018;24:679\u201390.","journal-title":"Nat Med"},{"key":"1194_CR31","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.medcli.2016.09.050","volume":"148","author":"M Sorigue","year":"2017","unstructured":"Sorigue M, Garcia O, Baptista MJ, Sancho J-M, Tapia G, Mate JL, et al. Similar prognosis of transformed and de novo diffuse large B-cell lymphomas in patients treated with immunochemotherapy. Med Clin. 2017;148:243\u20139.","journal-title":"Med Clin"},{"key":"1194_CR32","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1111\/j.1365-2141.2012.09054.x","volume":"157","author":"A Conconi","year":"2012","unstructured":"Conconi A, Ponzio C, Lobetti-Bodoni C, Motta M, Rancoita PMV, Stathis A, et al. Incidence, risk factors and outcome of histological transformation in follicular lymphoma. Br J Haematol. 2012;157:188\u201396.","journal-title":"Br J Haematol"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-024-01194-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-024-01194-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-024-01194-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,29]],"date-time":"2024-11-29T02:01:57Z","timestamp":1732845717000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-024-01194-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,29]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1194"],"URL":"https:\/\/doi.org\/10.1038\/s41408-024-01194-5","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,29]]},"assertion":[{"value":"4 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 November 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 November 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 November 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"212"}}